Navigation Links
Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
Date:9/17/2007

Next-Generation Once-Daily CCR5 Antagonist Designed to Block HIV Infection

of Immune System Cells

KENILWORTH, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that it has initiated two large Phase III clinical studies with vicriviroc, its investigational CCR5 antagonist, administered once-daily as a single 30 mg tablet in combination with an optimized background therapy that must include a protease inhibitor boosted by ritonavir in adult treatment-experienced HIV patients with R5-type virus only. Vicriviroc is a next-generation extracellular inhibitor of HIV infection designed to block entry of infectious virions into uninfected CD4 cells via antagonism of the CCR5 co-receptor.

The vicriviroc Phase III clinical program builds upon previous studies in HIV treatment-experienced patients, including a Phase II study (ACTG 5211) in which vicriviroc demonstrated potent and sustained viral suppression through 48 weeks of therapy.(1)

The two Phase III studies, known as VICTOR-E3 and VICTOR-E4 (Vicriviroc in Combination Treatment with an Optimized Antiretroviral Therapy Regimen in HIV- Infected Treatment-Experienced Subjects), will evaluate the virologic benefit of adding vicriviroc 30 mg once daily to an optimized background therapy compared to a control group receiving new optimized background therapy alone. The studies will also evaluate the safety and tolerability of vicriviroc compared to placebo. The optimized background therapy must include at least two drugs that are active, based on susceptibility testing. Patients coinfected with hepatitis C may be included in the studies and there are no exclusions of commonly prescribed drug
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
2. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
3. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
4. Malvern initiates European user group meetings for chemical imaging
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 The American Association for Homecare ... and Manufacturing has joined the AAHomecare Corporate Partner Program. ... Diamond have been actively involved in AAHomecare for ... has quickly grown into a major global manufacturer of ... allows AAHomecare to increase efforts on behalf of the ...
(Date:9/19/2014)... 19, 2014 Larry J. Merlo , President ... will speak before the National Press Club in ... recent move to stop selling tobacco products and its leadership ... health. "Dramatic changes in our health care system ... government," Merlo has said. "CVS Health has a truly unique ...
(Date:9/19/2014)... Sept. 19, 2014  Lpath, Inc. (NASDAQ: ... lipid-targeted therapeutics, announced today that it has entered ... of common stock and 3,605,042 unregistered warrants in ... for one registered share of common stock and ... of common stock will be $3.475.  The warrants ...
Breaking Medicine Technology:Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3
(Date:9/21/2014)... While public health authorities focus on the physical activity ... University of Montreal reveals that for children, playing has ... an activity that is fun, done alone or with ... or pleasure, but also to combat boredom, sadness, fear, ... of play, authorities put aside several aspects of play ...
(Date:9/21/2014)... Expert witness work is in! That ... its 2014 Expert Witness Fees & Practices Survey. With ... and compensation for qualified and credentialed expert witnesses has ... history. , The nearly 600 experts surveyed reported ... work, an increase of 3.2% from ExpertPages’ 2012 survey. ...
(Date:9/21/2014)... 2014 The asthma market saw ... it has become saturated with relatively efficacious standard ... (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and ... generic competition. However, the launch of seven novel ... therapies delivered by the next-generation inhalers will strongly ...
(Date:9/21/2014)... September 21, 2014 The Electronic ... and supports electronic medical records (EMR) and electronic ... federal healthcare legislation during the past five years ... during the five years to 2019. The 2009 ... Act established Medicare and Medicaid incentives to encourage ...
(Date:9/21/2014)... Market Research Report on ... 2009-2019 is a professional and in-depth market ... 49562-28-9) industry. The report firstly reviews the ... its classification, application and manufacturing technology.The report ... of Fenofibrate (CAS 49562-28-9) listing their product ...
Breaking Medicine News(10 mins):Health News:Narrow focus on physical activity could be ruining kids' playtime 2Health News:ExpertPages 2014 Survey Reports Expert Witness Hourly Fees Record All-Time Highs as Demand for Qualified Experts Continues to Grow 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 4Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4
... Medicare Strike Force Since March, WASHINGTON, Oct. 4 ... and operator of Direct Nursing Assistance Inc. of,Medicare fraud, ... and U.S. Attorney R. Alexander Acosta of the Southern ... trial, Rodolfo Aenlle, 47, was found guilty on all,counts ...
... IRIDEX,Corporation (Nasdaq: IRIX ) announced the ... the Company,s new independent auditor effective October,2, 2007. ... by the Audit Committee of the Company,s Board ... discussions with several,public accounting firms. BPM replaces PricewaterhouseCoopers ...
... in September Proving Successful, OWINGS MILLS, Md., Oct. ... that based on the current business outlook, the,Company is ... 31,2007. The Company expects to report revenue of $81 ... per diluted share. Previously, the Company,expected to report revenue ...
... part of what is ... nonprofit for teens., WILSONVILLE, Ore., Oct. 4 On Tuesday, October ... furniture,arcade games and supplies. These and other items, unused for at least ... the,Sexual Minority Youth Resource Center (SMYRC). Volunteer crews will move an ...
... Oct. 4 - A new American Heart,Association survey (1) shows consumer awareness ... an all-time high. But consumers still need,some key information to improve how ... the Bad Fats Are The survey shows that:, --While 92 ... jump from 84 percent in 2006 - only 21 percent ...
... revealing how toxic chemicals disrupt gene activity and other ... -- and why some individuals are particularly vulnerable. For ... more likely to experience side effects from certain medications, ... , How can this type of research -- known ...
Cached Medicine News:Health News:Miami Jury Convicts Medical Company Owner of Medicare Fraud 2Health News:Medifast Announces Updated Full Year 2007 Guidance 2Health News:Medifast Announces Updated Full Year 2007 Guidance 3Health News:Medifast Announces Updated Full Year 2007 Guidance 4Health News:Contents of the McGinnis Mansion Refurbishes Portland, Oregon Sexual Minority Youth Center 2Health News:Contents of the McGinnis Mansion Refurbishes Portland, Oregon Sexual Minority Youth Center 3Health News:Americans' Knowledge of Fats Growing But Still Insufficient 2Health News:Americans' Knowledge of Fats Growing But Still Insufficient 3
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride....
12% Tryptone, 24% Yeast Extract, 4.0% Glycerol. Supplied with 1 liter of 10x phosphate buffer (0190-1L)....
1.0% Casein digest (NZ amine), 0.5% Sodium Chloride, 0.5% Yeast Extract, 1.0% bacto casamino acids, 0.2% Mag. Sulfate....
S.O.C. Medium...
Medicine Products: